Chi Podcasts

Abhijit Patel of the Yale University School of Medicine recently spoke with CHI, on April 11, 2017 he will be speaking during the Cell-Free DNA in Clinical Oncology meeting at Molecular Diagnostics Europe. As a physician-scientist, Dr. Patel maintains an active clinical radiation oncology practice. His research group at Yale is working to develop and clinically validate novel noninvasive DNA- and RNA-based cancer diagnostics. In this podcast, Dr. Patel spoke to CHI to discuss the emerging technologies and challenges in liquid biopsy including developing robust and sensitive assays to detect early stage disease. For more information, please visit http://www.MolecularDXEurope.com/Clinical-Cell-Free-DNA/

Dexter Hadley of UCSF speaks to CHI on November, 29, 2016. Dr. Hadley will be speaking during the Bioinformatics track during the Molecular Medicine Triconference, February 19 - 24, in San Francisco, CA. Topics include developing a learning healthcare system to help make medicine more objective rather than subjective in terms of identifying melanoma and other symptoms, as well as creating an app to bring better personalized medicine to individuals. For more information, please visit http://www.TriConference.com/Bioinformatics-Big-Data/

Jaydev Thakkar of Amgen speaks to CHI on November 1st, 2016. Dr. Thakkar will be speaking during the Clinical Technology and Innovation conference at the SCOPE Summit, January 24-26, 2017 in Miami, FL. Topics include patient engagement from a data management perspective, using wearables to lower patient burden and tapping into novel endpoints. For more information, please visit http://www.SCOPESummit.com/Clinical-Data-Technology/

Brenda Yanak of Pfizer speaks to CHI on Oct 31, 2016. Dr. Yanak will be speaking during the Managing Precision Medicine Trials symposium at the SCOPE Summit, January 24-26, 2017 in Miami, FL. For more information, please visit http://www.SCOPESummit.com/

Diane Paskiet of West Pharmaceutical Services and Tilman Schlothauer of Roche speak to Cambridge Healthtech Institute. They are part of “It’s a Wrap”, the closing plenary panel discussion representing various R&D stages at PepTalk: The Protein Science Week, January 9-13 in San Diego, California. They each consider this question: What do you see as the next, most promising innovation in your field? For more details, please visit http://www.CHI-PepTalk.com/

Dr. Thomas Laue of University of New Hampshire, Bjørn Voldborg of Technical University of Denmark, and Dr. Andrew Fosberry of GlaxoSmithKline speak to Cambridge Healthtech Institute. They are part of “It’s a Wrap”, the closing plenary panel discussion representing various R&D stages at PepTalk: The Protein Science Week, January 9-13 in San Diego, California. They each consider this question: What do you see as the next, most promising innovation in your field?

CHI interviews Dr. Christopher Schofield, Head of Organic Chemistry in the Chemistry Research Laboratory at the University of Oxford, regarding his current work designing new demethylase inhibitors, current challenges, and his outlook for continued development in this space. Discussion Questions Include: How have you have seen this space evolve over the past few years? What are some demethylase targets currently being pursued by Medicinal Chemists? Can you please describe some of the work currently being conducted in your lab toward the discovery of new demethylase inhibitors? What challenges have been encountered designing small molecule histone demethylase inhibitors? How do you see this research evolving over the next few years? For more information, please visit http://www.DiscoveryOnTarget.com/Histone-Methyltransferases/

Bjørn Voldborg of Technical University of Denmark speaks to Cambridge Healthtech Institute on August 16, 2016. He will be a featured presenter at the Optimising Expression Platforms conference during PEGS Europe, 31 October - 4 November in Lisbon, Portugal. Topics include technological advancements in engineering CHO cell lines for increasing product yield and quality, challenges in recombinant protein expression over the last 20 years, and production of recombinant proteins as a science, not a service function.

Andrew Brooks of BioProcessing Solutions Alliance and Rutgers University speaks to Cambridge Healthtech Institute on August 3, 2016. Dr. Brooks will be presenting at the Leaders in Biobanking Congress, September 7-9 in Baltimore, Maryland. Topics include the evolution of biobanking quality control and standardization resources, goals and activities at Rutgers, challenges in biospecimen collection and storage for genomic research and clinical application, and harmonized biobanking to support precision medicine initiatives across multiple applications.

Anton Wellstein of Georgetown University Medical School speaks to Cambridge Healthtech Institute on August 1, 2016. He will be a presenter at the Leaders in Biobanking Congress, September 7-9 in Baltimore, MD. Topics include the importance of pre-analytical processing of samples, circulating nucleic acids in cancer treatment monitoring, and persistent challenges when linking cancer molecular markers with clinical information.

Susan Airhart of The Jackson Laboratory and Dr. Jens Rueter of Eastern Maine Medical Center speak to Cambridge Healthtech Institute on July 28, 2016. They will co-present a case study of their biobanker/R&D partnership at the Leaders in Biobanking Congress, September 7-9 in Baltimore, MD. Topics include the genesis and resources of The Jackson Laboratory’s PDX Consortium and the EMMC BioBank, their collaboration’s advancement of translational research, and how research with PDX models and biobank partnerships might evolve to contribute further to preclinical drug development and patient care. For more information, please visit http://www.HealthTech.com/Biobanking/Agenda#Day3

David Bick of HudsonAlpha speaks to CHI on July 20th, 2016. Dr. Bick will be speaking during the Health and Wellness Genomic Screening symposium at the Next Generation Diagnostics Summit, August 23-26th, in Washington DC. Topics include: Nik Volkner’s story of how genomic screening saved his life, the integration of genomic technologies into wellness programs and more. For more information, please vist http://www.NextGenerationDx.com/Health-Genomic-Screening/

Tim Minogue of the United States Army Medical Research Institute for Infectious Diseases speaks to CII on July 8, 2016. Tim Minogue will be speaking during the Molecular Diagnostics for Infectious Disease track at the Next Generation Diagnostics Summit, August 24th, in Washington DC. For more information, please visit http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics/

Dr. Ascierto will be discussing a historical perspective in treating melanoma and outline current clinical trials and real-world experience in immune checkpoint in melanoma, and detail what he considers some of the most exciting discoveries in the field. To learn more, please visit http://www.PEGSummitEurope.com/Cancer-Therapy/

Dr. Hatim Husain, Assistant Professor of Medicine in the department of Hematology and Oncology at UCSD spoke to CHI to discuss how using digital PCR has changed the way he conducts his research in oncology. He describes some of the benefits and challenges of integrating digital PCR into a laboratory, as well as discusses what he’s looking forward to seeing at the Digital PCR symposium. Dr. Husain will be speaking at the Digital PCR symposium taking place this August 26 at the Next Generation Dx Summit in Washington, DC. For details, please visit: http://www.NextGenerationDx.com/Digital-PCR/

Dr. Hinrich Abken will be discussing next generation CARs, comparison to other approaches, current efforts to improve on CAR molecules and advice for people in the field. For more information, please visit http://www.PEGSummitEurope.com/Phage-Display/

Jamie Platt of BRIDGenomics speaks to CHI on June 22, 2016. Dr. Platt will be speaking during the Health and Wellness Genomic Screening Symposium at the Next GenerationDiagnostics Summit, August 23-36, in Washington DC. Topics include next generation sequencing pricing, the challenges of implementing personalized medicine in the clinic and more. For more information, please visit http://www.NextGenerationDx.com/Health-Genomic-Screening

CHI interviewed Dr. Catherine Sanders, Director and Team Lead of Scientific Liaisons at Adaptive Biotechnologies on the utilization of high-throughput sequencing and expert bioinformatics profiling T-cell and B-cell receptors, also known as immunosequencing, to enable the development of a new generation of cancer immunotherapies. Discussion questions include: 1. Can you tell us a bit about Adaptive Biotechnologies, its origins, and where you are as a company now? 2. Can you please tell us about immunosequencing, and its applications in preclinical and clinical settings? 3. You are giving a luncheon presentation during the Cancer Immunotherapy and Combinations meeting, June 15-16, 2016 in Boston. Can you give us an idea of what you hope to convey to attendees during this lecture? 4. What challenges exist that may be overcome in the near future? What does the future of Adaptive and immunosequencing look like? For more information, please visit http://www.WorldPreclinicalCongress.com/Cancer-Immunothera

Chase Miller, Director of Research and Science, Eccles Department of Genetics, USTAR Center for Genetic Discovery, University of Utah School of Medicine spoke to CHI to discuss challenges in visualizing genomic data as well as how the IOBIO system helps address some of those challenges. He also discusses his favorite IOBIO application and what he’s looking forward to seeing at the conference. Dr. Miller is one of the developers of IOBIO and a speaker at the Data Visualization & Exploration Tools conference, taking place April 5-7 as part of the Bio-IT World Conference & Expo. For details, visit http://www.Bio-ITWorldExpo.com/Data-Visualization/

Dr. Jason Franasiak, Attending Physician at the Reproductive Medicine Associates of New Jersey, spoke to CHI to discuss the origins of germ theory and human microbiome research, specifically as it relates to human reproduction. He'll detail some of his research on the uteran microbiome during embryo implantation, future developments for diagnostics, and how other scientists may utilize his research and apply it to their own studies. Dr. Franasiak is one of our speakers for the Advances in Microbiome Diagnostics symposium, taking place August 26, 2016 in Washington, DC as part of the Next Generation Dx Summit. For details, visit www.NextGenerationDx.com/Microbiome-Diagnostics